BCL6 and neoplasm: As shown in Figures 7A, B, iRGD-Exo-BCL6 siRNA treatment remarkably reduced the expression of BCL6 and increased the expression of active caspase 3 in tumor tissues compared with the control or iRGD-Exo-siRNA NC group (Figures 7A, B).